Are You Covered? A Liability Insurance Primer for Compounders | Essential: The Pharmacy Compounding Podcast
- 30m
- Transcript
Summary
Written by a model from the transcript; not yet reviewed.
This episode covers key legal, regulatory, and business developments for compounding pharmacies, focusing on liability insurance. The host, Andrew Cantor, shares legislative updates, including the death of an anti-compounding bill in California and modifications to the federal Safe Drugs Act, alongside looming FDA guidance on natural thyroid medications and peptides. In the main segment, Scott Brunner speaks with Kristen Jones, Associate Vice President at Pharmacist Mutual Insurance Company, about the unique liability risks compounding pharmacies face compared to traditional retail dispensers. They discuss how ingredients, calculations, sterility, volume, and new business models like telehealth impact insurance coverage and why owners must communicate operational changes to their agents.
- Review your insurance coverage with your agent regularly, especially when adding new equipment or business operations. 28:07
- Notify your insurance claims department immediately if you receive a state board letter or patient complaint. 23:56
- Focus on ingredient selection and calculation accuracy, as these account for nearly half of compounding errors. 11:03
- Recognize that having a valid prescription from a prescriber does not eliminate a pharmacist's independent professional liability. 25:00
Chapters
- 0:05Podcast Intro and Compounding News
Hosts introduce the episode, give a quick compounding news update, and preview the main interview.
- 0:52California Anti-Compounding Bill Dies
Andrew reports that the California anti-compounding bill AB 1990 has quietly died, sparing compounding pharmacies from new restrictions.
- 2:00Federal Safe Drugs Act Revisions
Discussion of the Safe Drugs Act, its revisions, and how it now allows shortage drug compounding and requires MedWatch reporting.
- 3:11Biologics Status of Thyroid Meds
Explains FDA’s classification of animal-derived thyroid meds as biologics, limiting compounding and affecting patient options.
- 5:25Peptide Compounding Outlook
Overview of FDA PCAC recommendations for peptides, uncertainty about implementation, and potential impact on compounding pharmacies.
- 9:34Risk Profile of Compounding vs Dispensing
Kristen explains how compounding creates a higher risk profile due to formulation responsibility and potential for batch errors.
- 12:01Sterile vs Non‑Sterile Coverage
Details how Pharmacist Mutual handles sterile compounding endorsements, premium differences, and underwriting practices.
- 15:32Common Misunderstandings About Coverage
Kristen lists typical owner misconceptions, emphasizes communication with agents, and covers equipment, business interruption, and employment liability.
- 17:50GLP‑1 and Telehealth Risks
Discussion of compounded GLP‑1 drugs, telehealth contracts, and how these new activities affect insurance underwriting and risk.
- 20:41Coverage Limits for Unapproved Substances
Kristen explains that insurance does not cover activities outside legal or regulatory frameworks and advises caution before compounding unapproved drugs.
- 22:48Reporting and Notification Requirements
Outlines when pharmacy owners should notify insurers about FDA letters, state board actions, or patient complaints to maintain coverage.
- 27:52Lightning Round: Three Key Steps
Kristen gives a concise checklist for owners: insurance checkup, operational risk control, and open communication with agents.
Highlights
- 9:46
Compounding Liability Differencesinsight
The guest explains that unlike retail dispensaries that sell pre-manufactured drugs, compounding pharmacies take on manufacturing responsibilities, meaning a single calculation or ingredient error can affect multiple patients.
- 11:03
Calculations Over Sterilitydata
Data shows that calculation and ingredient selection errors contribute to nearly half of compounding sector errors, whereas sterile compounding claims are less frequent though more severe.
- 13:27
Sterile Compounding Endorsementsstrategy
Professional liability policies do not automatically cover sterile compounding; pharmacies must obtain an extra endorsement and pay additional premium due to the higher risk profile.
- 16:54
Clean Room Incident Storystory
The guest shares an example where a perpetrator cut through a wall into a clean room, knocking it down for months and illustrating the importance of business interruption insurance.
- 20:54
Unapproved Substances Coverageinsight
The guest warns that insurance policies are not safety nets for illegal activities, meaning compounding substances outside federal or state law may result in coverage denials.
- 23:32
Filing Notice Only Claimsstrategy
Unlike homeowners insurance where filing claims might raise rates, professional liability carriers evaluate notice-only potential claims differently, so getting insurers involved early is encouraged.
Quotes
“AB 1990, that's the bill's number.”
Unnamed speaker · 0:59 “With compounding, the pharmacy becomes part of the manufacturing process itself.”
Unnamed speaker · 9:46 “If you are compounding a substance that's not legally permitted under either federal or state law, you may have coverage issues that arise depending on the facts, policy language, and circumstances involved if there is a claim that's filed.”
Unnamed speaker · 21:04 “The fact that a prescription, you have a prescription in your hand, doesn't eliminate your obligation to evaluate whether that therapy is appropriate, if the compounded preparation is legal, and whether it's prepared safely and accurately.”
Unnamed speaker · 25:17
Sponsored segments
- APC 30:06–30:34
About this episode
This episode looks at some smart ways to regulate pharmacy when it comes to med spas and pop-up clinics — ways that won’t cut patients off from their meds. We also look at the latest news on the thyroid-extract front, what’s happening with peptide compounding, and a bill in California that could bode well for pharmacists nationwide. Then we talk with Kristen Jones, PharmD, from Pharmacists Mutual about how insurance companies view compounding, and why compounders are taking a bigger risk than they might realize if they’re compounding peptides. Pharmacists Mutual: https://pmuw.comJoin APC: a4pc.org/joinStay up to date on these topics and more at: a4pc.org/news
Transcript
5,080 words · 4 speakers
Topics
- FDA
- peptides
- GLP-1s
- California
- PCAC
- Telehealth
- Pharmacy Podcast Network
- Essential Pharmacy Compounding News
- Alliance for Pharmacy Compounding
- Pharmacist Mutual Insurance Company
Page updated · transcript and summary are machine-generated